Ceres plans to go public on Feb. 9, raising as much as $132 million on the Nasdaq under the symbol CERE.
The sudden demise of California’s redevelopment agencies continues to send shock waves across the Tri-Counties.
Inphi Corp., the Santa Clara-based chip firm with a large engineering force in Thousand Oaks, ousted its CEO on Feb. 1 as it announced that profits plummeted by 93 percent in 2011. Inphi designs chips aimed at packing more memory into Internet servers and increasing bandwidth in the Internet backbone. The company announced that Ford Read More →
Thousand Oaks-based energy crop developer Ceres has plans to make its debut on the Nasdaq on Feb. 8 under the symbol CERE and raise $132 million. Shares in the company, which uses genetic marking technology to speed the development of non-food energy crops such as drought-resistant switchgrass, are expected hit the markets at between $21 Read More →
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”26-07-2011″ enddate=”26-01-2012″ width=”300″ height=”245″] Biotech giant Amgen, which said earlier on Thursday that it would pay $1.2 billion for leukemia drugmaker Micromet, reported fourth-quarter earnings that missed analyst expectations. The Thousand Oaks-based company said fourth-quarter profits fell 8.5 percent to $934 million, or $1.08 per share, on lower sales of Read More →
[wikichart align=”right” ticker=”NASDAQ:AMGN” showannotations=”true” livequote=”true” startdate=”26-07-2011″ enddate=”26-01-2012″ width=”300″ height=”245″] Thousand Oaks-based Amgen is buying a leukemia drug maker for $1.2 billion in a bid to boost its blockbuster drug lineup. Amgen, the world’s largest biotech company, said Jan. 26 that it will purchase Maryland-based Micromet, maker of an experimental leukemia drug. Investors of Microment will Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.